JP Morgan Maintains Neutral on Molecular Partners, Lowers Price Target to $4.5
Molecular Partners Analyst Ratings
SVB Leerink Downgrades Molecular Partners to Market Perform, Lowers Price Target to $8
Molecular Partners Analyst Ratings
Credit Suisse Cuts Price Target on Molecular Partners to CHF6 From CHF8, Lowers Probability of Success for Ensovibep to 5%, Keeps Neutral Rating
No Data